KMOB SAN LUIS OBISPO

NIHOUT OCPICI 48

NIHOU NW N United States Pat

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE: United States Proper and Trademark Office Address Commissioner for Patients T.O. Box 1450 Alexandra, Viginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/829,631	04/10/2001	David R. Sibley	NIH047.1CP1C1	7640
20995 - 75	7590 17/09/2003		examiner	
KNOBBE MARTENS OLSON & BEAR LLP			allen, marianne p	
2040 MAIN STREET FOURTBENTH FLOOR			ART UNIT	PAPER NUMBER
IRVINE, CA			1691	,
			DATE MAILED: 12/00/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

U.S. Peleni and Tredemark Offic PTOL-326 (Rev. 11-03)

and a stage of

And Orlander

Application/Control Number: 09/829,631

Art Unit: 1631

Page 2

DETAILED ACTION

Applicant's arguments filed 6/23/03 have been fully considered but they are not persuasive.

Claims 17-28 are under consideration by the examiner.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Oath/Declaration

It is maintained that in view of originally filed claims 1-16 in this application, this application remains a continuation-in-part application and a new oath is required as set forth in the prior Office action. The status as a continuation-in-part application will not change even if the presently pending or any future claims have basis in the parent applications and are granted benefit of that priority date. Once again, as filed, this application constituted a continuation-in-part application. Applicant's arguments on this point are not germane nor do they dispute that originally filed claims 1-16 were not supported by the parent application.

Priority

Applicant is requested to update the status of all applications referenced throughout the specification.

Claim Rejections - 35 USC § 112

Claims 17, 20, and 22-28 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

antifikaan organisti (1900) oo ka ka saabii ka saa Aanaa aa saabii ka s

Application/Control Number: 09/829,631

Art Unit: 1631

Page 3

For the purposes of discussing the new matter rejection, basis for the present claims will be considered with respect to basis in WO 94/10310. All page references will be with respect to this document.

Claim 17, part (c) is directed to nucleotide sequences that hybridize under particular conditions and encode a serotonin receptor protein St-B17.

Example 9 at page 22 discloses using the rat St-B17 serotonin receptor sequence fragments and conditions named in part (c) to clone the human sequence from a particular human genomic library (Stratagene # 946205). There is no contemplation of generic St-B17 sequences encoding receptors from other species that would hybridize to the recited restriction fragments under the recited conditions. This specific example is not considered to demonstrate contemplation of the generic invention now claimed.

None of the portions of the specification pointed to by applicant show contemplation for the embodiments encompassed by part (c).

Claim Rejections - 35 USC § 102

Claims 17, 20, and 22-28 are rejected under 35 U.S.C. 102(b) as being anticipated by either of Sibley et al. (WO 94/10310) or Sibley et al. (EP 0 558,912 B1).

As presently written, these claims are entitled to benefit of the instant filing date of 4/10/01 and both Sibley et al. (WO 94/10310) and Sibley et al. (EP 0 558,912 B1) are valid prior art under 35 U.S.C. 102(b). Claim 17, part (c) is not supported by the instant application nor any of the priority documents and is properly denied benefit.

Both Sibley et al. (WO 94/10310) and Sibley et al. (EP 0 558,912 B1) disclose cloning and expression of the rat and human St-B17 serotonin receptor. Vectors and host cells are

Application/Control Number: 09/829,631

Art Unit: 1631

Page 4

abstract, claims, and figures. In particular, claim 1 part (c) of Sibley et al. (EP 0 558,912 B1) reflects the same language as instant claim 17, part (c). It is noted that the instant application does not claim priority to this document and what is contemplated in this European patent is not found in the instant application, parent application 08/428,242, PCT/US93/10296 nor parent application 07/970,338.

Conclusion

Claims 18, 19, and 21 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marianne P. Allen whose telephone number is 703-308-0666. The examiner can normally be reached on Monday-Thursday, 5:30 am - 1:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on 703-308-4028. The fax phone number for the organization where this application or proceeding is assigned is 703-305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Marianne P. Allen Primary Examiner Art Unit 1631

mpa